LEV, a relatively new AED also used to control seizures during glioblastoma multiforme (GBM) treatment, has been reported to modulate HDAC levels by silencing O6-methylguanine-DNA methyltransferase (MGMT), which, in turn, improves the activity of the alkylating agent temozolomide (TMZ), i.e., the most effective chemotherapy to treat GBM [210]. Here, MGMT is linked to glioblastoma.